UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults

PloS one, 2021-05, Vol.16 (5), p.e0251963-e0251963

2021

Volltextzugriff (PDF)

Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: the mHealth Screening To Prevent Strokes (mSToPS) trial

The American heart journal, 2016-05, Vol.175, p.77-85

2016

Volltextzugriff (PDF)

Novel oral anticoagulants and reversal agents: Considerations for clinical development

The American heart journal, 2015-06, Vol.169 (6), p.751-757

2015

Volltextzugriff (PDF)

NOAC Monitoring, Reversal Agents, and Post-Approval Safety and Effectiveness Evaluation: A Cardiac Safety Research Consortium Think Tank

The American heart journal, 2016-07, Vol.177, p.74-86

2016

Volltextzugriff (PDF)

Three year clinical outcomes in a nationwide, observational, siteless clinical trial of atrial fibrillation screening—mHealth Screening to Prevent Strokes (mSToPS)

PloS one, 2021-10, Vol.16 (10), p.e0258276

2021

Volltextzugriff (PDF)

Digital recruitment and enrollment in a remote nationwide trial of screening for undiagnosed atrial fibrillation: Lessons from the randomized, controlled mSToPS trial

Contemporary clinical trials communications, 2019-06, Vol.14, p.100318-100318, Article 100318

2019

Volltextzugriff (PDF)

Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers

Thrombosis and haemostasis, 2004-06, Vol.91 (6), p.1090

2004

Volltextzugriff (PDF)

Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube

Clinical pharmacology in drug development, 2014-07, Vol.3 (4), p.321-327

2014

Volltextzugriff (PDF)

Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions

Annals of the New York Academy of Sciences, 2013-07, Vol.1291 (1), p.42-55

2013

Volltextzugriff (PDF)

Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects

Journal of the American College of Cardiology, 2003-02, Vol.41 (4), p.557-564

2003

Volltextzugriff (PDF)

Healthcare resource utilization following ECG sensor patch screening for atrial fibrillation

Heart rhythm O2, 2020-12, Vol.1 (5), p.351-358

2020

Volltextzugriff (PDF)

Torcetrapib Produces Endothelial Dysfunction Independent of Cholesteryl Ester Transfer Protein Inhibition

Journal of cardiovascular pharmacology, 2010-05, Vol.55 (5), p.459-468

2010

Volltextzugriff (PDF)

Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2018-07, Vol.320 (2), p.146

2018

Volltextzugriff (PDF)

Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model

Thrombosis and haemostasis, 2006-03, Vol.95 (3), p.447

2006

Volltextzugriff (PDF)

No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran

Clinical pharmacokinetics, 2003, Vol.42 (5), p.485-492

2003

Volltextzugriff (PDF)

Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion

Drug metabolism and disposition, 2006-05, Vol.34 (5), p.775

2006

Volltextzugriff (PDF)

Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans

International journal of clinical pharmacology and therapeutics, 2012-08, Vol.50 (8), p.584

2012

Volltextzugriff (PDF)

Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban

Clinical cardiology (Mahwah, N.J.), 2015-02, Vol.38 (2), p.63-68

2015

Volltextzugriff (PDF)

Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates

Thrombosis research, 2007-01, Vol.119 (1), p.121-127

2007

Volltextzugriff (PDF)

A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays

Thrombosis research, 2005, Vol.115 (1), p.9-18

2005

Volltextzugriff (PDF)

The Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor, Are Unaffected by a Single Dose of Alcohol

Journal of clinical pharmacology, 2004-04, Vol.44 (4), p.388-393

2004

Volltextzugriff (PDF)

A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin

The Journal of pharmacology and experimental therapeutics, 1998-01, Vol.284 (1), p.356

1998

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers

European journal of clinical pharmacology, 2007-06, Vol.63 (6), p.571-581

2007

Volltextzugriff (PDF)

No Pharmacokinetic or Pharmacodynamic Interaction Between Digoxin and the Oral Direct Thrombin Inhibitor Ximelagatran in Healthy Volunteers

Journal of clinical pharmacology, 2004-08, Vol.44 (8), p.935-941

2004

Volltextzugriff (PDF)

Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor

The Journal of pharmacology and experimental therapeutics, 1999-05, Vol.289 (2), p.695

1999

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(30)

Publikationsform

Sprache

Englisch
(48)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(35)
Life Sciences & Biomedicine
(33)
Humans
(31)
Male
(29)
Female
(19)
Adult
(17)
Pharmacology & Pharmacy
(17)
Administration, Oral
(14)
Benzylamines
(14)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Azetidines - Pharmacology
(12)
Pharmacology. Drug Treatments
(12)
Ximelagatran
(12)
Azetidines - Administration & Dosage
(11)
Azetidines - Pharmacokinetics
(11)
Thrombin - Antagonists & Inhibitors
(11)
Cardiovascular System & Cardiology
(10)
Animals
(9)
Anticoagulants - Administration & Dosage
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults

Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: the mHealth Screening To Prevent Strokes (mSToPS) trial

Novel oral anticoagulants and reversal agents: Considerations for clinical development

NOAC Monitoring, Reversal Agents, and Post-Approval Safety and Effectiveness Evaluation: A Cardiac Safety Research Consortium Think Tank

Three year clinical outcomes in a nationwide, observational, siteless clinical trial of atrial fibrillation screening—mHealth Screening to Prevent Strokes (mSToPS)

Digital recruitment and enrollment in a remote nationwide trial of screening for undiagnosed atrial fibrillation: Lessons from the randomized, controlled mSToPS trial

Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers

Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube

Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions

Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects

Healthcare resource utilization following ECG sensor patch screening for atrial fibrillation

Torcetrapib Produces Endothelial Dysfunction Independent of Cholesteryl Ester Transfer Protein Inhibition

Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial

Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model

No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran

Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion

Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans

Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban

Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates

A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays

The Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor, Are Unaffected by a Single Dose of Alcohol

A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin

Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers

No Pharmacokinetic or Pharmacodynamic Interaction Between Digoxin and the Oral Direct Thrombin Inhibitor Ximelagatran in Healthy Volunteers

Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor

Suchergebnisse filtern